MAPT and Alzheimer disease: As for secondary tauopathies, which include AD, LBD, PD, Down syndrome, Huntington’s disease, myotonic dystrophy, and Niemann–Pick disease type C, no pathogenetic mutations can be detected in the MAPT gene, nor does tau play any primary pathogenic role, and the development of tau pathology occurs in response to other pathogenic events (e.g., the formation of amyloid beta-Aβ, the main component of neuritic plaques in AD) [6,24].